Northwest Biotherapeutics (NWBO) Total Debt (2010 - 2026)

Northwest Biotherapeutics' Total Debt history runs 17 years deep, the most recent figure standing at $7.2 million for Q1 2026.

• On a quarterly basis, Total Debt fell 56.47% year-over-year to $7.2 million in Q1 2026; TTM through Mar 2026 was $7.2 million, a 56.47% decrease from a year earlier, with the FY2025 full-year figure at $21.7 million, down 1.02% from the prior year.
• Total Debt fell to $7.2 million in Q1 2026 per NWBO's latest filing, from $21.7 million in the prior quarter.
• Across five years, Total Debt topped out at $29.9 million in Q3 2024 and bottomed at $7.2 million in Q1 2026.
• The 5-year median for Total Debt is $21.7 million (2025), against an average of $20.9 million.
• Across the five-year window, Total Debt soared 101.24% in 2023 and slumped 56.47% in 2026, its largest moves.
• Year by year, Total Debt stood at $14.7 million in 2022, then surged by 101.24% to $29.5 million in 2023, then declined by 25.51% to $22.0 million in 2024, then fell by 1.02% to $21.7 million in 2025, then plunged by 66.88% to $7.2 million in 2026.
• Per Business Quant, the three latest NWBO Total Debt figures stand at $7.2 million (Q1 2026), $21.7 million (Q4 2025), and $16.9 million (Q3 2025).